Cerecor Inc., a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation. It also offers Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension; and Flexichamber. The company is developing CERC-301, an orphan neurological indication for controlling neurologic adaptation; CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy; and two preclinical stage development candidates, CERC-406 and CERC-425 potential for the treatment of motoric and non-motoric symptoms of Parkinson's disease, as well as other psychiatric and neurological conditions. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone410-522-8707
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.33 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/1/2019 (Estimated)
OptionableOptionable
Cerecor (NASDAQ:CERC) Frequently Asked Questions
What is Cerecor's stock symbol?
Cerecor trades on the NASDAQ under the ticker symbol "CERC."
How were Cerecor's earnings last quarter?
Cerecor Inc (NASDAQ:CERC) posted its quarterly earnings results on Monday, August, 14th. The company reported ($0.14) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.29) by $0.15. The firm earned $0.16 million during the quarter. Cerecor had a negative return on equity of 93.99% and a negative net margin of 218.47%. View Cerecor's Earnings History.
When is Cerecor's next earnings date?
What guidance has Cerecor issued on next quarter's earnings?
Cerecor issued an update on its FY 2019 earnings guidance on Monday, March, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $20-22 million.
What price target have analysts set for CERC?
1 brokers have issued 1-year target prices for Cerecor's shares. Their predictions range from $9.00 to $9.00. On average, they anticipate Cerecor's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 52.0% from the stock's current price. View Analyst Price Targets for Cerecor.
What is the consensus analysts' recommendation for Cerecor?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerecor in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerecor.
Has Cerecor been receiving favorable news coverage?
Press coverage about CERC stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cerecor earned a news impact score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the stock's share price in the next few days.
Who are some of Cerecor's key competitors?
Some companies that are related to Cerecor include Clementia Pharmaceuticals (CMTA), Kiniksa Pharmaceuticals (KNSA), Amphastar Pharmaceuticals (AMPH), MacroGenics (MGNX), Deciphera Pharmaceuticals (DCPH), Vanda Pharmaceuticals (VNDA), Dicerna Pharmaceuticals (DRNA), Alder Biopharmaceuticals (ALDR), Apellis Pharmaceuticals (APLS), Principia Biopharma (PRNB), Advanz Pharma (CXRXF), Omeros (OMER), Lexicon Pharmaceuticals (LXRX), Radius Health (RDUS) and Y-mAbs Therapeutics (YMAB).
What other stocks do shareholders of Cerecor own?
Who are Cerecor's key executives?
Cerecor's management team includes the folowing people:
- Mr. Peter S. Greenleaf, CEO & Director (Age 49)
- Ms. Mariam E. Morris, Consultant (Age 51)
- Dr. Solomon H. Snyder, Founder and Chairman of Scientific Advisory Board (Age 80)
- Dr. Barbara S. Slusher, Founder and Member of Scientific Advisory Board (Age 54)
- Mr. Joseph M. Miller CPA, Chief Financial Officer
Who are Cerecor's major shareholders?
Cerecor's stock is owned by a number of of retail and institutional investors. Top institutional investors include Opaleye Management Inc. (5.36%), Prosight Management LP (0.75%), Geode Capital Management LLC (0.23%), Geode Capital Management LLC (0.23%), O Shaughnessy Asset Management LLC (0.09%) and BlackRock Inc. (0.08%). Company insiders that own Cerecor stock include Armistice Capital Master Fund, Armistice Capital, Llc, James Archie Harrell Jr, Matthew V Phillips, Peter Greenleaf and Robert Jr Moscato. View Institutional Ownership Trends for Cerecor.
Which institutional investors are selling Cerecor stock?
CERC stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, O Shaughnessy Asset Management LLC and Cambridge Investment Research Advisors Inc.. View Insider Buying and Selling for Cerecor.
Which institutional investors are buying Cerecor stock?
CERC stock was purchased by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Prosight Management LP, Geode Capital Management LLC, Geode Capital Management LLC, Northern Trust Corp and BlackRock Inc.. Company insiders that have bought Cerecor stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc, James Archie Harrell Jr, Matthew V Phillips, Peter Greenleaf and Robert Jr Moscato. View Insider Buying and Selling for Cerecor.
How do I buy shares of Cerecor?
Shares of CERC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cerecor's stock price today?
One share of CERC stock can currently be purchased for approximately $5.92.
How big of a company is Cerecor?
Cerecor has a market capitalization of $252.51 million and generates $18.33 million in revenue each year. The company earns $11.86 million in net income (profit) each year or $0.42 on an earnings per share basis.
What is Cerecor's official website?
How can I contact Cerecor?
Cerecor's mailing address is 540 Gaither Road Suite 400, Rockville MD, 20850. The company can be reached via phone at 410-522-8707 or via email at [email protected]
MarketBeat Community Rating for Cerecor (NASDAQ CERC)
MarketBeat's community ratings are surveys of what our community members think about Cerecor and other stocks. Vote "Outperform" if you believe CERC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERC will underperform the S&P 500 over the long term. You may vote once every thirty days.
